Core Viewpoint - The stock of Giant Bio (02367) has dropped over 4%, currently trading at 58.9 HKD with a transaction volume of 272 million HKD, following allegations regarding the quality of its collagen products [1] Group 1: Company Developments - Huaxi Bio has officially responded to the controversy surrounding Dr. Hao Yu, revealing that it has conducted tests on related products in collaboration with multiple third-party testing agencies, which indicated that the recombinant collagen content did not meet standards [1] - Huaxi Bio has submitted dozens of test reports to the National Medical Products Administration, highlighting the seriousness of the findings [1] - In May, beauty blogger Dr. Hao Yu accused Giant Bio's product "Collagen Stick" of having a recombinant collagen content of only 0.0177%, significantly below the 0.1% non-trace addition standard, and lacking the core amino acid glycine [1] Group 2: Company Responses - Giant Bio quickly denied the allegations, asserting that its products comply with regulations and that internal testing results exceed the 0.1% standard [1] - On June 1, Huaxi Bio publicly supported Dr. Hao Yu, indicating a division in the industry regarding the quality of Giant Bio's products [1] - Following a series of exchanges, on June 23, Giant Bio acknowledged that its existing quality standards, testing methods, and labeling have shown limitations in certain aspects [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 上市公司的名称：华熙生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：华熙生物 股票代码：688363 信息披露义务人： 名称：华熙昕宇投资有限公司 住所：北京市密云区冯家峪镇政府南文化中心院内115室 通讯地址：北京市朝阳区建国门外大街甲6号华熙国际中心D座35层 信息披露义务人之一致行动人： 姓名：赵燕 通讯地址：北京市朝阳区建国门外大街甲6号华熙国际中心D座33层 信息披露义务人之一致行动人： 名称：上海琰泽企业管理合伙企业（有限合伙） 一、本报告系信息披露义务人依据《中华人民共和国证券法》、《上市公司收购管理办法》、《公开发 行证券的公司信息披露内容与格式准则第15号——权益变动报告书》及相关的法律和法规编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报告书已全面披露了信息 披露义务人在华熙生物科技股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通过任何其他方式增加或减少 其在华熙生物科技股份有限公司中 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-036 华熙生物科技股份有限公司 关于控股股东增持股份进展暨权益变动触及 5%整数 倍的提示性公告 投资者华熙昕宇投资有限公司及其一致行动人保证向本公司提供的信息真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加☑ | 比例减少□ | | --- | --- | --- | | 权益变动前合计比例 | 59.17% | | | 权益变动后合计比例 | 60.01% | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否☑ | | 是否触发强制要约收购义务 | 是□ | 否☑ | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他_____ ...

华熙生物科技股份有限公司简式权益变动报告书 华熙生物科技股份有限公司 简式权益变动报告书 上市公司的名称：华熙生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：华熙生物 股票代码：688363 信息披露义务人： 名称：华熙昕宇投资有限公司 住所：北京市密云区冯家峪镇政府南文化中心院内 115 室 通讯地址：北京市朝阳区建国门外大街甲 6 号华熙国际中心 D 座 35 层 信息披露义务人之一致行动人： 姓名：赵燕 通讯地址：北京市朝阳区建国门外大街甲 6 号华熙国际中心 D 座 33 层 信息披露义务人之一致行动人： 名称：上海琰泽企业管理合伙企业（有限合伙） 住所：上海市嘉定区安亭镇墨玉路 185 号 1 层 J9995 室 通讯地址：北京市朝阳区建国门外大街甲 6 号华熙国际中心 D 座 35 层 权益变动性质：信息披露义务人增持股份 简式权益变动报告书签署日期：2025 年 9 月 19 日 1 华熙生物科技股份有限公司简式权益变动报告书 信息披露义务人声明 一、本报告系信息披露义务人依据《中华人民共和国证券法》、《上市公司收 购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 ...

（原标题：华熙生物(688363.SH)：华熙昕宇增持403.68万股公司股份） 格隆汇9月23日丨华熙生物(688363.SH)公布，公司于近日收到控股股东华熙昕宇投资有限公司(以下简 称"华熙昕宇")出具的《关于权益变动触及5%整数倍刻度的告知函》及《简式权益变动报告书》。华熙 昕宇于2025年8月27日至2025年9月19日期间通过集中竞价方式增持公司股份4,036,842股，增持后持有公 司股份287,536,842股，与其一致行动人上海琰泽企业管理合伙企业(有限合伙)、赵燕女士合计持有公司 股份289,031,485股，占公司总股本的比例由59.17%增加至60.01%，权益变动触及5%的整数倍刻度。 ...

华熙生物公告，华熙昕宇投资有限公司通过集中竞价方式增持公司股票403.68万股。此次权益变动后， 华熙昕宇及其一致行动人合计持有公司股份2.89亿股，占公司总股本的60.01%。此次增持计划自2025年 8月8日起的6个月内，增持金额不低于2亿元，不超过3亿元。 ...

格隆汇9月23日丨华熙生物(688363.SH)公布，公司于近日收到控股股东华熙昕宇投资有限公司(以下简 称"华熙昕宇")出具的《关于权益变动触及5%整数倍刻度的告知函》及《简式权益变动报告书》。华熙 昕宇于2025年8月27日至2025年9月19日期间通过集中竞价方式增持公司股份4,036,842股，增持后持有公 司股份287,536,842股，与其一致行动人上海琰泽企业管理合伙企业(有限合伙)、赵燕女士合计持有公司 股份289,031,485股，占公司总股本的比例由59.17%增加至60.01%，权益变动触及5%的整数倍刻度。 ...

Investment Rating - The report maintains a "Positive" outlook on the beauty and personal care industry, highlighting the resilience of domestic brands and the impact of new consumption trends [2]. Core Insights - The beauty and personal care sector experienced a robust recovery in H1 2025, with a retail sales growth of 2.9%, reversing the previous decline due to favorable consumption policies and improved income expectations [5][6]. - Domestic brands are gaining market share, with top local brands now competing closely with international counterparts, indicating a significant shift in consumer preferences [10][11]. - The report categorizes companies into three groups based on performance: those with strong brand matrices benefiting from multi-brand strategies, those capitalizing on consumer trends like domestic brands and collagen products, and those showing signs of strategic improvement [20][23]. Summary by Sections Industry Overview - The beauty market is projected to grow steadily, with a forecasted retail sales decline of 1.1% in 2024, followed by a recovery in H2 2025 [5][6]. - The domestic market share is expected to increase, with local brands achieving significant breakthroughs in both skincare and makeup segments [10][11]. Company Performance - **Cosmetics Sector**: - Major companies like Up Beauty and Proya reported revenue growth of 17.3% and 7.2% respectively in H1 2025, with net profits increasing by 30.6% and 13.8% [20][21]. - Other notable performers include Marubi and Water Sheep, with revenue growth of 30.8% and 9.0% respectively [21][22]. - **Personal Care Sector**: - Companies like Ruibin and Zhenjia showed remarkable growth, with Ruibin's revenue increasing by 67.6% and Zhenjia's by 157.11% in H1 2025 [5][20]. - **Medical Aesthetics Sector**: - Companies like Aimeike and Langzi reported mixed results, with Aimeike's revenue declining by 21.6% while Langzi's net profit surged by 64.1% [20][24]. Investment Recommendations - The report recommends investing in companies with strong brand matrices and low PE multiples, such as Up Beauty and Proya, as well as those benefiting from the Douyin traffic boost like Marubi and Water Sheep [20][24]. - It also suggests focusing on high-value segments and innovative products from brands like Ruibin and Furuida, and highlights opportunities in the maternal and infant sector with companies like Shengbeila and Haiziwang [20][24].

Group 1 - The overall performance of domestic beauty and skincare companies in the first half of 2025 remains stable, with Proya and Shiseido maintaining their positions as industry leaders, while Juzhibio leads in profit [1][2] - Proya's main brand shows a slight decline, indicating a near ceiling for single-brand growth in the domestic market, while Maogeping has entered the top five, representing the high-end trend in domestic beauty [2][10] - The financial performance of major companies shows varied results, with Proya reporting revenue of 5.362 billion yuan (up 7.21%), Shiseido at 4.108 billion yuan (up 17.30%), and Juzhibio at 3.113 billion yuan (up 22.50%) [3][4] Group 2 - Juzhibio's profit reached 1.182 billion yuan, a 20.60% increase, while Proya's profit was 799 million yuan (up 13.80%) and Maogeping's profit was 670 million yuan (up 36.10%) [5][6] - The beauty industry is facing challenges with brand positioning and organizational restructuring, particularly for established companies like Huaxi Biological and Beitaini, which have seen significant declines in performance [25][30] - Maogeping has successfully expanded into high-end skincare and fragrance markets, with a focus on diversifying its business to reduce reliance on single products [20][23] Group 3 - The emergence of new active ingredients, such as ergothioneine, is gaining attention in the beauty industry, with companies investing in research and development to innovate [39][42] - Marketing strategies are shifting towards brand strength and celebrity endorsements, with companies like Proya and Marubi actively engaging high-profile brand ambassadors [51][53] - Companies are increasingly focusing on building comprehensive sales channels that integrate online and offline strategies, as well as domestic and international markets, to adapt to changing consumer behaviors [58][60]

Core Viewpoint - Huaxi Biological experienced a stock price decline of 2.00% on September 23, with a current price of 54.34 CNY per share and a total market capitalization of 26.174 billion CNY [1] Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company operates in the fields of microbial fermentation and cross-linking technology, developing bioactive materials that contribute to human health [1] - The company has established a full industry chain business system, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end-users [1] Business Revenue Composition - The revenue composition of Huaxi Biological is as follows: - Skin science innovation transformation business: 40.34% - Medical terminal products: 29.76% - Raw material products: 27.70% - Others: 2.17% - Other (supplement): 0.03% [1] Stock Performance - Year-to-date, Huaxi Biological's stock price has increased by 6.70%, but it has seen a decline of 7.00% over the last five trading days and 6.60% over the last twenty days [1] Financial Performance - For the first half of 2025, Huaxi Biological reported a revenue of 2.261 billion CNY, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million CNY, down 35.38% year-on-year [2] Shareholder Information - As of July 31, the number of shareholders of Huaxi Biological was 32,500, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2] Dividend Distribution - Since its A-share listing, Huaxi Biological has distributed a total of 1.138 billion CNY in dividends, with 528 million CNY distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, major shareholders include: - Huaxia SSE Sci-Tech Innovation Board 50 ETF (588000) - 10.6429 million shares, down 244,800 shares - E Fund SSE Sci-Tech Innovation Board 50 ETF (588080) - 7.9777 million shares, up 227,800 shares - Huabao CSI Medical ETF (512170) - 6.4329 million shares, newly entered - Hong Kong Central Clearing Limited - 5.7990 million shares, up 1.3124 million shares [3]